Glaukos (NYSE:GKOS) PT Raised to $112.00 at BTIG Research

Glaukos (NYSE:GKOS) had its price target boosted by investment analysts at BTIG Research from $107.00 to $112.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research’s price target would indicate a potential upside of 6.49% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 price target on shares of Glaukos in a research note on Wednesday, April 3rd. Citigroup upped their target price on shares of Glaukos from $107.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 25th. Wells Fargo & Company increased their target price on shares of Glaukos from $103.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday. StockNews.com lowered Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. Finally, Mizuho raised their price objective on Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.00.

Glaukos Stock Performance

NYSE GKOS traded up $6.26 during trading hours on Thursday, hitting $105.17. 440,276 shares of the stock were exchanged, compared to its average volume of 650,488. The company has a quick ratio of 4.78, a current ratio of 5.34 and a debt-to-equity ratio of 0.77. The company has a market cap of $5.28 billion, a price-to-earnings ratio of -37.98 and a beta of 1.08. Glaukos has a 12-month low of $45.47 and a 12-month high of $108.22. The stock has a 50-day moving average of $92.71 and a 200 day moving average of $82.43.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The business had revenue of $85.60 million for the quarter, compared to analyst estimates of $79.60 million. During the same quarter in the previous year, the firm posted ($0.59) EPS. The business’s revenue for the quarter was up 15.8% on a year-over-year basis. As a group, equities research analysts forecast that Glaukos will post -2.16 earnings per share for the current year.

Insider Activity

In related news, CFO Alex R. Thurman sold 434 shares of Glaukos stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the sale, the chief financial officer now owns 54,166 shares in the company, valued at approximately $5,163,644.78. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO Alex R. Thurman sold 474 shares of Glaukos stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total value of $42,835.38. Following the completion of the sale, the chief financial officer now owns 54,916 shares of the company’s stock, valued at $4,962,758.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Alex R. Thurman sold 434 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $95.33, for a total value of $41,373.22. Following the completion of the transaction, the chief financial officer now owns 54,166 shares of the company’s stock, valued at $5,163,644.78. The disclosure for this sale can be found here. Insiders have sold 232,881 shares of company stock worth $21,965,491 over the last three months. 6.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Glaukos

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC purchased a new stake in Glaukos in the fourth quarter valued at approximately $608,000. Natixis Advisors L.P. raised its position in shares of Glaukos by 4.0% in the 3rd quarter. Natixis Advisors L.P. now owns 33,979 shares of the medical instruments supplier’s stock worth $2,557,000 after buying an additional 1,298 shares during the period. State of New Jersey Common Pension Fund D boosted its holdings in Glaukos by 26.9% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 41,883 shares of the medical instruments supplier’s stock valued at $3,329,000 after acquiring an additional 8,884 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Glaukos by 5.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 386,790 shares of the medical instruments supplier’s stock valued at $29,106,000 after acquiring an additional 20,415 shares during the period. Finally, Lisanti Capital Growth LLC acquired a new stake in Glaukos during the third quarter worth about $6,367,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.